Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,903 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Outcomes of salvage radical prostatectomy after initial irreversible electroporation treatment for recurrent prostate cancer.
van Riel LAMJG, Geboers B, Kabaktepe E, Blazevski A, Reesink DJ, Stijns P, Stricker PD, Casanova J, Dominguez-Escrig JL, de Reijke TM, Scheltema MJ, Oddens JR. van Riel LAMJG, et al. Among authors: casanova j. BJU Int. 2022 Nov;130(5):611-618. doi: 10.1111/bju.15759. Epub 2022 May 13. BJU Int. 2022. PMID: 35474600 Free PMC article.
Long-term oncological results of treatment for high-risk prostate cancer using radical prostatectomy in a cancer hospital.
Rubio-Briones J, Ramírez-Backhaus M, Gómez-Ferrer A, Mir C, Domínguez-Escrig J, Collado A, Iborra I, Casanova J, Solsona E, Mascarós JM, Calatrava A. Rubio-Briones J, et al. Among authors: casanova j. Actas Urol Esp (Engl Ed). 2018 Oct;42(8):507-515. doi: 10.1016/j.acuro.2018.02.007. Epub 2018 Apr 7. Actas Urol Esp (Engl Ed). 2018. PMID: 29631913 English, Spanish.
Identification of miR-187 and miR-182 as biomarkers of early diagnosis and prognosis in patients with prostate cancer treated with radical prostatectomy.
Casanova-Salas I, Rubio-Briones J, Calatrava A, Mancarella C, Masiá E, Casanova J, Fernández-Serra A, Rubio L, Ramírez-Backhaus M, Armiñán A, Domínguez-Escrig J, Martínez F, García-Casado Z, Scotlandi K, Vicent MJ, López-Guerrero JA. Casanova-Salas I, et al. Among authors: casanova j. J Urol. 2014 Jul;192(1):252-9. doi: 10.1016/j.juro.2014.01.107. Epub 2014 Feb 8. J Urol. 2014. PMID: 24518785
Importance of previous transurethral resection of the prostate before eerpe.short-term functional outcomes in a single surgeon series.
Ramírez Backhaus M, Juan Escudero J, Palmero Martí JL, Ortíz Rodríguez IM, Rubio Briones J, Stolzenburg JU, Benedicto Redón A, Domínguez Escrig J, Collado Serra A, Gómez-Ferrer Á, Casanova J, Rodríguez Torreblanca C, Solsona Narbón E. Ramírez Backhaus M, et al. Among authors: casanova j. Arch Esp Urol. 2012 Sep;65(7):675-83. Arch Esp Urol. 2012. PMID: 22971763 English, Spanish.
Optimizing the clinical utility of PCA3 to diagnose prostate cancer in initial prostate biopsy.
Rubio-Briones J, Borque A, Esteban LM, Casanova J, Fernandez-Serra A, Rubio L, Casanova-Salas I, Sanz G, Domínguez-Escrig J, Collado A, Gómez-Ferrer A, Iborra I, Ramírez-Backhaus M, Martínez F, Calatrava A, Lopez-Guerrero JA. Rubio-Briones J, et al. Among authors: casanova salas i, casanova j. BMC Cancer. 2015 Sep 11;15:633. doi: 10.1186/s12885-015-1623-0. BMC Cancer. 2015. PMID: 26362197 Free PMC article.
Validation of a 2-gene mRNA urine test for the detection of ≥GG2 prostate cancer in an opportunistic screening population.
Rubio-Briones J, Borque-Fernando A, Esteban LM, Mascarós JM, Ramírez-Backhaus M, Casanova J, Collado A, Mir C, Gómez-Ferrer A, Wong A, Aragón F, Calatrava A, López-Guerrero JA, Groskopf J, Schalken J, Van Criekinge W, Domínguez-Escrig J. Rubio-Briones J, et al. Among authors: casanova j. Prostate. 2020 May;80(6):500-507. doi: 10.1002/pros.23964. Epub 2020 Feb 20. Prostate. 2020. PMID: 32077525
Optimizing prostate cancer screening; prospective randomized controlled study of the role of PSA and PCA3 testing in a sequential manner in an opportunistic screening program.
Rubio-Briones J, Casanova J, Dumont R, Rubio L, Fernandez-Serra A, Casanova-Salas I, Domínguez-Escrig J, Ramírez-Backhaus M, Collado A, Gómez-Ferrer A, Iborra I, Monrós JL, Ricós JV, Solsona E, Salas D, Martínez F, Lopez-Guerrero JA. Rubio-Briones J, et al. Among authors: casanova salas i, casanova j. Actas Urol Esp. 2014 May;38(4):217-23. doi: 10.1016/j.acuro.2013.09.007. Epub 2013 Oct 27. Actas Urol Esp. 2014. PMID: 24169211 Clinical Trial. English, Spanish.
PCA3 as a second-line biomarker in a prospective controlled randomized opportunistic prostate cancer screening programme.
Rubio-Briones J, Casanova J, Martínez F, Domínguez-Escrig JL, Fernández-Serra A, Dumont R, Ramírez-Backhaus M, Gómez-Ferrer A, Collado A, Rubio L, Molina A, Vanaclocha M, Sala D, Lopez-Guerrero JA. Rubio-Briones J, et al. Among authors: casanova j. Actas Urol Esp. 2017 Jun;41(5):300-308. doi: 10.1016/j.acuro.2016.10.008. Epub 2017 Mar 23. Actas Urol Esp. 2017. PMID: 28342633 Clinical Trial. English, Spanish.
1,903 results